← Leaderboards
Xuefei Huang
Michigan State University
$14,687,150
Attributed
$17,124,701
Total exposure
10
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2M · FY2005–25$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$17,124,701 · 10
By mechanism
R01$13,297,334 · 6
U01$2,811,574 · 1
R21$445,050 · 1
R35$417,243 · 1
R03$153,500 · 1
Top collaborators
- Linda C Hsieh-Wilson5 shared
- Hao Xu3 shared
- Rajendar K Deora1 shared
- Gerald B Pier1 shared
Others in their field
Top investigators on “Structure”
- David Heimbrook · Leidos Biomedical Research, Inc.$475,333,582
- Barton F Haynes · Duke University$444,977,767
- Lawrence Corey · Fred Hutchinson Cancer Center$334,646,086
- Gary D Acton · University Of California-Davis$320,373,312
- Mitchell J Malone · Texas A&M Research Foundation$320,373,312
- Michael David Hughes · Harvard University D/B/A Harvard School Of Public Health$315,257,203
Research focus
StructurePolysaccharidesBaseCarbohydratesPatternLinkDesignPlayReactionOligosaccharidesMalignant NeoplasmsCell SurfaceBiological ProcessBiologicalAntigensVaccinesBacteriophagesProteinsImmune ResponseRoutePreventPropertyEventEnzymes
Grant awards (50)
Deciphering the amine/acetylation code of PNAG through comprehensive libraries of synthetic oligosaccharides for effective anti-microbial vaccines$837,644
R01 · FY2025 · AI · contact PI
Carbohydrate based multi-component vaccine against Bordetella pertussis$780,834
R01 · FY2025 · AI · contact PI
Syntheses of homogeneous proteoglycan like glycopeptide and glycoprotein libraries for microarray studies$417,243
R35 · FY2025 · GM · contact PI
Enabling synthesis and biological studies of homogeneous heparan sulfate and chondroitin sulfate glyco-polypeptides and proteoglycans$290,733
R01 · FY2024 · GM · contact PI
Engineering bacteriophage Qβ conjugates with tumor associated carbohydrate antigens as multi-component anti-cancer vaccines$541,578
R01 · FY2023 · CA · contact PI
Enabling synthesis and biological studies of homogeneous heparan sulfate and chondroitin sulfate glyco-polypeptides and proteoglycans$302,450
R01 · FY2023 · GM · contact PI
Synthetic glycan conjugates with bacteriophage Qbeta for broad spectrum anti-salmonella vaccines$300,000
R01 · FY2023 · AI · contact PI
Engineering bacteriophage Qβ conjugates with tumor associated carbohydrate antigens as multi-component anti-cancer vaccines$447,430
R01 · FY2022 · CA · contact PI
Enabling synthesis and biological studies of homogeneous heparan sulfate and chondroitin sulfate glyco-polypeptides and proteoglycans$307,785
R01 · FY2022 · GM · contact PI
Synthetic glycan conjugates with bacteriophage Qbeta for broad spectrum anti-salmonella vaccines$300,000
R01 · FY2022 · AI · contact PI
Enabling synthesis and biological studies of homogeneous heparan sulfate and chondroitin sulfate glyco-polypeptides and proteoglycans$320,341
R01 · FY2021 · GM · contact PI
Synthetic glycan conjugates with bacteriophage Qbeta for broad spectrum anti-salmonella vaccines$300,000
R01 · FY2021 · AI · contact PI
Enabling synthesis and biological studies of homogeneous heparan sulfate and chondroitin sulfate glyco-polypeptides and proteoglycans$212,182
R01 · FY2021 · GM · contact PI
Engineering bacteriophage Qβ conjugates with tumor associated carbohydrate antigens as multi-component anti-cancer vaccines$100,000
R01 · FY2021 · CA · contact PI
Engineering bacteriophage Qβ conjugates with tumor associated carbohydrate antigens as multi-component anti-cancer vaccines$446,307
R01 · FY2020 · CA · contact PI
Synthetic glycan conjugates with bacteriophage Qbeta for broad spectrum anti-salmonella vaccines$300,000
R01 · FY2020 · AI · contact PI
Engineering bacteriophage Qβ conjugates with tumor associated carbohydrate antigens as multi-component anti-cancer vaccines$420,237
R01 · FY2019 · CA · contact PI
Generation of active immunity against cytotoxic oligomeric tau species$375,606
R01 · FY2019 · CA · contact PI
Synthetic glycan conjugates with bacteriophage Qbeta for broad spectrum anti-salmonella vaccines$300,000
R01 · FY2019 · AI · contact PI
Stereoselective Assembly of Challenging Glycosidic Linkages with Earth-Abundant Metal Catalysts$143,000
R21 · FY2019 · GM
Stereoselective Assembly of Challenging Glycosidic Linkages with Earth-Abundant Metal Catalysts$60,175
R21 · FY2019 · GM
Expedited Synthesis of Glycosaminoglycans Containing Defined Sulfation Domains$725,108
U01 · FY2018 · GM
Engineering bacteriophage Qβ conjugates with tumor associated carbohydrate antigens as multi-component anti-cancer vaccines$420,593
R01 · FY2018 · CA · contact PI
Homogeneous Heparan Sulfate Glycopeptides: Synthetic and Functional Studies$255,208
R01 · FY2018 · GM · contact PI
Stereoselective Assembly of Challenging Glycosidic Linkages with Earth-Abundant Metal Catalysts$241,875
R21 · FY2018 · GM
Expedited Synthesis of Glycosaminoglycans Containing Defined Sulfation Domains$197,354
U01 · FY2018 · GM
Expedited Synthesis of Glycosaminoglycans Containing Defined Sulfation Domains$609,004
U01 · FY2017 · GM
Homogeneous Heparan Sulfate Glycopeptides: Synthetic and Functional Studies$278,907
R01 · FY2017 · GM · contact PI
Expedited Synthesis of Glycosaminoglycans Containing Defined Sulfation Domains$615,012
U01 · FY2016 · GM
Homogeneous Heparan Sulfate Glycopeptides: Synthetic and Functional Studies$280,201
R01 · FY2016 · GM · contact PI
Homogeneous Heparan Sulfate Glycopeptides: Synthetic and Functional Studies$103,458
R01 · FY2016 · GM · contact PI
Virus like particles as carriers for carbohydrate based anti-Salmonella vaccines$76,750
R03 · FY2016 · AI · contact PI
Expedited Synthesis of Glycosaminoglycans Containing Defined Sulfation Domains$665,096
U01 · FY2015 · GM
Virus-Like Particle Based Antigen Display as Multi-component Anticancer Vaccines$479,723
R01 · FY2015 · CA · contact PI
Homogeneous Heparan Sulfate Glycopeptides: Synthetic and Functional Studies$342,948
R01 · FY2015 · GM · contact PI
Virus like particles as carriers for carbohydrate based anti-Salmonella vaccines$76,750
R03 · FY2015 · AI · contact PI
Virus-Like Particle Based Antigen Display as Multi-component Anticancer Vaccines$464,527
R01 · FY2014 · CA · contact PI
Virus-Like Particle Based Antigen Display as Multi-component Anticancer Vaccines$447,677
R01 · FY2013 · CA · contact PI
Chemoenzymatic Synthesis of Heparin and Heparan Sulfate Oligosaccharides$287,378
R01 · FY2013 · GM · contact PI
Virus-Like Particle Based Antigen Display as Multi-component Anticancer Vaccines$476,018
R01 · FY2012 · CA · contact PI
Chemoenzymatic Synthesis of Heparin and Heparan Sulfate Oligosaccharides$297,801
R01 · FY2012 · GM · contact PI
Virus-Like Particle Based Antigen Display as Multi-component Anticancer Vaccines$501,816
R01 · FY2011 · CA · contact PI
Chemoenzymatic Synthesis of Heparin and Heparan Sulfate Oligosaccharides$297,801
R01 · FY2011 · GM · contact PI
Chemoenzymatic Synthesis of Heparin and Heparan Sulfate Oligosaccharides$221,083
R01 · FY2010 · GM · contact PI
Development of New Carbohydrate Synthesis Methodologies$239,605
R01 · FY2009 · GM · contact PI
Development of New Carbohydrate Synthesis Methodologies$239,473
R01 · FY2008 · GM · contact PI
Development of New Carbohydrate Synthesis Methodologies$255,970
R01 · FY2007 · GM · contact PI
Development of New Carbohydrate Synthesis Methodologies$264,384
R01 · FY2006 · GM · contact PI
Development of New Carbohydrate Synthesis Methodologies$6,936
R01 · FY2006 · GM · contact PI
Development of New Carbohydrate Synthesis Methodologies$252,700
R01 · FY2005 · GM